Wellness & Lifestyle – Page 18

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY 08/01/2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Clinical Updates Wellness & Lifestyle

Expanding Nonoperative Management in Mismatch Repair–Deficient Early-Stage Solid Tumors: Phase 2 Evidence for Neoadjuvant PD-1 Blockade

By MedXY 08/01/2025

Neoadjuvant PD-1 blockade with dostarlimab enabled organ preservation and high recurrence-free survival in early-stage mismatch repair–deficient (dMMR) solid tumors, extending nonoperative management beyond rectal cancer.

Clinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.

Clinical Updates Wellness & Lifestyle

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.

Clinical Updates Wellness & Lifestyle

Cilta-Cel CAR-T療法で再発・難治性多発性骨髄腫の長期予後：患者の3分の1が5年以上の寛解を達成

By MedXY 08/01/2025

最近のJ Clin Oncol研究では、cilta-cel治療を受けたRRMM患者の約33%が5年以上の無増悪生存を達成し、持続的な反応と有望なバイオマーカーが示されました。

Clinical Updates Wellness & Lifestyle

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Clinical Updates Wellness & Lifestyle

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

By MedXY 08/01/2025

Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.

Clinical Updates Wellness & Lifestyle

As-Needed Albuterol–Budesonide Therapy in Mild Asthma: Clinical Impact and Comparative Evidence

By MedXY 08/01/2025

As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.

Clinical Updates Wellness & Lifestyle

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.

Clinical Updates Wellness & Lifestyle

Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis

By MedXY 08/01/2025

A recent multicenter trial demonstrates methotrexate's noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.